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Postoperative nausea and vomiting are two of the most common complications after general anaesthesia for major gynaecological surgery. J Antiemeties, such as hydroxyzine, droperidol and metoclopramide, are used to prevent postoperative nausea and vomiting, but their effectiveness varies. 
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5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that has been proved to be effective in the prevention of cancer chemotherapy-induced nausea and vomiting. 6 Recently, we have demonstrated that granisetron 40 txg" kg -~ /v effectively treats postoperative nausea and vomiting,7 and that this drug is superior to metoclopramide in the long:te-r~ prevention of postoperative nausea and vomiting.S This\study was designed to assess the antiemetic efficacy and 'safety of granisetron for preventing postoperative nausea and vomiting ha a randomized, double-blind comparison with placebo or two different doses (1.25 mg and 2.5 mg) of droperidol which have previously been reported to reduce the incidence of postoperative nausea and vomiting in patients undergoing major gynaecological surgery, i-4
Methods
After approval of our institutional review board, 100 female patients, ASA physical status I or II, aged 23 to 67 yr, and scheduled for major gynaecological surgery gave informed consent. No patient had cardiovascular, respiratory, renal, hepatic, neurological diseases nor had received any antiemetie drug within 24 hr of surgery.
As premeditation, all patients received atropine sulphate 0.5 mg im 30 min before induction of anaesthesia. In the operating room, patients were placed in the lateral decubitus position. A 17-gange Tuohy needle was inserted at either Ia_3 or L3_4 interspace with the loss of resistance technique, and an 18-gauge epidural catheter was placed cephalad (approximately 5 cm) through the needle. Correct placement of the catheter was confirmed by administration of a test dose of 2 ml lidocaine 1.5%. After catheter placement, patients were placed in the supine position. The patients received, in a randomized, doubleblind manner, a single dose of either granisetron (40 ttg' kg-l), droperidol (1.25 mg or 2.5 mg) or placebo (saline)/v over a two to five minute period immediately before induction of anaesthesia. Anaesthesia was induced with thiopentone 5 mg-kg -~ /v and vecuronium 0.2 rag" kg -t /v was used to facilitate tracheal intubation. After tracheal intubation, anaesthesia was maintained with nitrous oxide 4 L" min-l, oxygen 2 L-min-~ and isoflurane 0.5-2.0% (inspired concentration). Ventilation was controlled meehanically and was adjusted to maintain PETCO 2 between 35 "and 40 mmHg with an anaesthetic/respiratory gas analyzer (Capnomac Ultima, Datex, Finland). After the circulation had stabilized, 10--15 ml lidocaine 1.5% were injected through the epidural catheter. Muscle relaxants were used as needed. Isoflurane inhalation ceased approximately 10 minutes before the end of surgery. At the end of surgery, nitrous oxide administration was stopped, and atropine sulphate 0.02 mg. kg -I/v and neostigmine 0.04 rag-kg -I/v were administered for reversal of muscle relaxation, and the tracheas were extubated. The awakening time was defined as the period between the cessation of nitrous oxide administration and eyes opening on command. Rectal temperature was monitored and maintained at 37 + I~ throughout surgery. Rescue antiemetics (e.g., metoclopramide) were given if two or more episodes of vomiting occurred within 24 hr of anaesthesia. For postoperative analgesia, a continuous epidural infusion with a mixture of 40 ml bupivaeaine 0.25 mg and morphine 0.1 mg. kg -~ was started after the end of surgery at a rate of 1.7 ml. hr -t (Drug infusion balloon catheter, Dib international, Japan). In addition, patients in all groups were allowed to receive indomethacin (50 mg, pr) for intolerable pain.
Postoperatively, at three and 24 hr after recovery from anaesthesia, episodes of nausea and vomiting were experienced by the patients and recorded during the fast three (0-3) hr and the next 21 (3-24) hr after anaesthesia by direct questioning by anaesthetists who did not know which antiemetics the patients had received. Retching was not assessed as a separate entity, and patients who experienced retching were classified as nauseous. 9 The details of any adverse effect throughout the study (0-24 hr after anaesthesia) were also recorded by either general questioning or by spontaneous report of the patients. Drowsiness/sedation was graded on a two-point scale and was assessed as 0 = awake, 1 = drowsy/sedative.
Patient demographic data were analyzed with one-way analysis of variance (ANOVA) and Students' t test. The frequency of postoperative nausea and vomiting and the incidence of adverse events were compared with nonparametrie tests (X 2, Kruskall-Wallis). A P value of <0.05 was considered significant. All values were expressed as mean + SD.
Results
Except for the awakening time, patient characteristics and surgical procedures were not different among the treatment groups (Table I ). The awakening time in patients who had received droperidol 2.5 mg was prolonged compared with the placebo group (P < 0.05).
During 0-3 hr after recovery from anaesthesia, the frequencies of postoperative nausea and vomiting in patients who had received granisetron (12%), droperidol 1.25 mg (16%) and droperidol 2.5 mg (12%) were lower than in those who had received placebo (60%) (P < 0.05) (Table II) . During 3-24 hr after anaesthesia, these frequencies of the granisetron (8%) and the droperidol 2.5 mg (12%) groups were different from the placebo group (44%) (P < 0.05). However, no differences in frequencies were observed between the droperidol 1.25 mg (36%) and the placebo groups (Table HI) emetics were given in either group. The frequency of use of indomethaein was 4--8% in each group. The most frequently reported adverse events were headache, dizziness and drowsiness/sedation (Table IV) . Except for a high incidence of drowsiness/sedation in patients who had received droperidol 2.5 mg, there was no difference in any adverse event among the treatment groups. In addition, no extrapyramidal symptoms were observed in patients who had received 1.25 rng and 2.5 mg of droperidol.
Discussion
The main findings of this study were that during 0-3 hr after recovery from anaesthesia, the frequencies of postoperative nausea and vomiting in patients who had received granisetron, droperidol 1.25 nag or droperidol 2.5 mg were lower than those who had received placebo (P < 0.05), but there were no differences in these frequencies between the droperidol 1.25 mg and the placebo groups during 3-24 after anaesthesia.
The aetiology of nausea and vomiting after gynaecological surgery performed under general anaesthesia is probably mulfifactorial. ~ A number of factors which inelude age, obesity, operative procedure, anaesthetic technique and postoperative pain are thought to increase the frequency of these postoperative symptoms. In this study, however, the treatment groups were similar for patient characteristics, surgical procedure, anaesthetic administered and analgesics used postoperatively. Therefore, the differences in the frequencies of postoperative nausea and vomiting among the groups can be attributed to the difference in the agents tested.
Granisetron has already been reported to be effective in the treatment of nausea and vomiting in patients receiving cytotoxic drugs. 6 It has also been reported reeently that it is effective in reducing the incidence of these symptoms after surgery. 8 The results of this study, with an administration of placebo or granisetron, showed that frequencies of nausea and vomiting during the fLrSt three and the next 21 hr after anaesthesia in patients who had received granisetron were lower than those who had received placebo. This was in agreement with our previous study, s Although the precise mechanism of granisetron in preventing postoperative nausea and vomiting is not known, it has been suggested that this drug may act on sites containing 5-HT3 receptors with demonstrated antiemetic effects. 10 It is known that effective doses of granisetron are between 40 and 80 ~g" kg -1 for the treatment of cancer therapy-induced nausea and vomiting, z0 As previously demonstrated, granisetron 40 I~g" kg -I was the optimal effective dose for preventing postoperative nausea and vomiting. 7 Therefore, this dose of granisetron was administered in this study.
It has been reported by Korttila et al. 3 and Madej et al. 1 that 1.25 mg and 2.5 mg of droperidol reduce the incidence of nausea and vomiting following gynaecological surgery. In this study, therefore, the antiemetic efficacy of granisetron in the prevention of postoperative nausea and vomiting was compared with these doses of droperidol.
This study also demonstrated that frequencies of postoperative nausea and vomiting in patients who had received granisetron were similar to those who had received 1.25 mg and 2.5 mg of droperidol during 0-3 hr after recovery from anaesthesia, and that these frequencies of the droperidol 1.25 mg group were higher than those of granisetron group during 3-24 hr after anaesthesia. Thus, the efficacy of granisetron 40 ~g. kg -I for preventing postoperative nausea and vomiting was almost equal to droperidol 2.5 mg. The exact reason for difference in effectiveness between 1.25 mg and 2.5 mg of droperidol is not known, but may be related to the short elimination half-life of this agent (2.2 hr in healthy volunteers). 12 In this study, the prolongation in awakening time and the reported drowsiness/sedation as an adverse event were observed in patients who had received droperidol 2.5 mg, and there were no differences in awakening time and frequencies of side-effects among the remaining three groups. Although the delayed awakening time (approximately 3 rain) al~er administering droperidol 2.5 mg is less clinically important, side-effects which include drowsiness/ sedation observed in these patients are undesirable. The use of droperidol is associated with possible extrapyramidal symptoms, 15 but these symptoms were not observed in either group of this study. Therefore, the use of granisetron for preventing postoperative nausea and vomiting appears to be safe. Our hospital pharmacy pays 10,200 u for granisetron 3 mg (approximately 60 ~g-kg-') and 175 u for droperidol 2.5 rag. Thus, granisetron is much more expensive than droperidol. However, on the basis of our results, administration of granisetron was safe in preventing postoperative nausea and vomiting. Therefore, the decision on antiemetics should not be limited to these costs but also should take into comideration the preferences of patients.
In conclusion, this study suggests that preoperative administration of granisetron is superior to that of droperidol in terms of efficacy and safety for preventing postoperative nausea and vomiting. 
